Sector News

Gilead’s ‘open to suggestion’ on its next big M&A splash

May 1, 2015
Life sciences
On pace to reap $29 billion in revenue this year thanks to its surging hepatitis C franchise, Gilead Sciences has the cash to pull off a big deal or two, and management is eyeing a slew of late-stage opportunities.
 
The Big Biotech wowed analysts with a $7.6 billion sales quarter, good for 52% annual growth, leading to an obvious question: What’s Gilead going to do with all that money? Expand its pipeline, R&D chief Norbert Bischofberger said on a conference call, pointing to “myriad external possibilities” out there on the market.
 
Gilead has largely shied away from big-ticket dealmaking since its $11 billion acquisition of Pharmasset–from which it acquired the then-inchoate hep C blockbusters Sovaldi and Harvoni. But, thanks in part to its bountiful cash flow, the company is now more agnostic about deal size, President and COO John Milligan said, worrying less about price than whether a target is “the right fit for Gilead.”
 
“We typically like things where we can have impact on Phase III and where we can accelerate those products either into the approval process or into greater indications after the approval process,” Milligan told analysts. “… So, we’re open to suggestion–there have been many mentioned out there–but I would say that I want to stick very closely to kinds of (therapeutic) areas we’re in here today.”
 
That likely means more asset-minded deals, like Gilead’s $600 million buyout of the cancer biotech Calistoga Pharmaceuticals or its $470 million partnership with the NASH-focused Phenex Pharmaceuticals.
 
But, walking back comments made last year, Gilead is no longer ruling out major M&A.
 
And, as Milligan mentioned, analysts are happy to suggest just where Gilead should direct its checkbook. Bernstein’s Geoffrey Porges has urged the company to take a $45 billion plunge on Vertex Pharmaceuticals to get a foothold in orphan drugs, and other analysts have pointed to NASH leader Intercept Pharmaceuticals, which has a market cap of roughly $6 billion.
 
By Damian Garde
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.